{"entity":{"id":"signatur-biosciences","kind":"company","name":"Signatur Biosciences","aka":[],"tldr":"Signatur turns complex gene-expression tests, starting with breast cancer prognosis, into simple PCR tests that a local hospital lab can run in days.","summary":"Signatur Biosciences develops decentralised precision diagnostics that translate multi-gene expression signatures into PCR-based assays runnable in local hospital laboratories, with a first product for early breast cancer prognosis to guide chemotherapy decisions, cutting turnaround from weeks in a centralised laboratory to days at a fraction of the cost. The company is London-based and remains active in the YC directory; clinical validation data have not been published in a primary source found at the time of checking.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/signatur-biosciences"},{"label":"Official website","url":"https://www.signatur.bio"}],"tags":["yc"],"related":[],"cancers":["breast-hr-positive"],"sections":["diagnostics"],"technologies":["companion-diagnostic"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"London","country":"GB","companyType":"diagnostics","website":"https://www.signatur.bio","stage":"startup","ycBatch":"S22","investors":["y-combinator"],"funding":[]},"route":"/companies/signatur-biosciences/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"}],"company":[{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/"}]}}